Abstract:Background: Lung adenocarcinoma ranks as the second most widespread form of cancer globally, accompanied by a significant mortality rate. Several studies have shown that T cell exhaustion is associated with immunotherapy of tumours. Consequently, it is essential to comprehend the possible impact of T cell exhaustion on the tumor microenvironment. The purpose of this research was to create a TEX-based model that would use single-cell RNA-seq (scRNA-seq) and bulk-RNA sequencing to explore new possibilities for assessing the prognosis and immunotherapeutic response of LUAD patients. Methods: RNA-seq data from LUAD patients was downloaded from the Cancer Genome Atlas (TCGA) database and the National Center for Biotechnology Information (GEO). 10X scRNA sequencing data, as reported by Bischoff P et al., was utilized for down-sampling clustering and subgroup identification using TSNE. TEX-associated genes were identified through gene set variance analysis (GSVA) and weighted gene correlation network analysis (WGCNA). We utilized LASSO-Cox analysis to establish predicted TEX features. External validation was conducted in GSE31210 and GSE30219 cohorts. Immunotherapeutic response was assessed in IMvigor210, GSE78220, GSE35640 and GSE100797 cohorts. Furthermore, we investigated differences in mutational profiles and immune microenvironment between various risk groups. We then screened TEXRS key regulatory genes using ROC diagnostic curves and KM survival curves. Finally, we verified the differential expression of key regulatory genes through RT-qPCR. Results: Nine TEX genes were identified as highly predictive of LUAD prognosis and strongly correlated with disease outcome. Univariate and multivariate analysis revealed that patients in the low-risk group had significantly better overall survival rates compared with those in the high-risk group, highlighting the model's ability to independently predict LUAD prognosis. Our analysis revealed significant variation in the biological function, mutational landscape, and immune cell infiltration within the tumor microenvironment of both high-risk and low-risk groups. Additionally, immunotherapy was found to have a significant impact on both groups, indicating strong predictive efficacy of the model. Conclusions: The TEX model showed good predictive performance and provided a new perspective for evaluating the efficacy of preimmunization, which provides a new strategy for the future treatment of lung adenocarcinoma.

Identification and validation of tryptophan metabolism-related lncRNAs in lung adenocarcinoma prognosis and immune response

Identification and validation of tryptophan-related gene signatures to predict prognosis and immunotherapy response in lung adenocarcinoma reveals a critical role for PTTG1

A Novel Neutrophil Extracellular Traps-Related Lncrna Signature Predicts Prognosis in Patients with Early-Stage Lung Adenocarcinoma

Identification and Validation of Immune-Related LncRNA Prognostic Signature for Lung Adenocarcinoma

Prediction of Hepatocellular Carcinoma Prognosis and Immunotherapeutic Effects Based on Tryptophan Metabolism-Related Genes.

Identification of Key Immune Cells Infiltrated in Lung Adenocarcinoma Microenvironment and Their Related Long Noncoding RNA

Combination of transcriptome and Mendelian inheritance reveals novel prognostic biomarker of CTLA-4-related lncRNAs and protective role of nitrogen metabolism pathway in lung adenocarcinoma development

Identification and Verification of Metabolism-related Immunotherapy Features and Prognosis in Lung Adenocarcinoma

Development and Validation of an Endoplasmic Reticulum Stress Long Non-Coding RNA Signature for the Prognosis and Immune Landscape Prediction of Patients with Lung Adenocarcinoma

Integrated bioinformatics analysis and experimental validation to understand tryptophan metabolism-related genes in hepatocellular carcinoma

Long Non-Coding RNAs in Lung Cancer: The Role in Tumor Microenvironment

Identification of T-cell exhaustion-related genes and prediction of their immunotherapeutic role in lung adenocarcinoma

Identification of Fatty Acid Metabolism-Related lncRNAs as Biomarkers for Clinical Prognosis and Immunotherapy Response in Patients With Lung Adenocarcinoma

Identification of Biomarkers for the Detection of Early Stage Lung Adenocarcinoma by Microarray Profiling of Long Noncoding RNAs.

Identification and Validation of Long Non-Coding RNA LCIIAR as a Biomarker in LUAD

Identification of an Autophagy-Related lncRNA Prognostic Signature and Related Tumor Immunity Research in Lung Adenocarcinoma

Identification and Validation of a Novel Immune-Related Four-lncRNA Signature for Lung Adenocarcinoma

Identification key genes, key miRNAs and key transcription factors of lung adenocarcinoma

Construction of an immune-related lncRNA signature as a novel prognosis biomarker for LUAD

Identification of prognostic genes in lung adenocarcinoma immune microenvironment

LncRNA LINC01833 is a Prognostic Biomarker and Correlates with Immune Infiltrates in Patients with Lung Adenocarcinoma by Integrated Bioinformatics Analysis